A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies
NCT04353102
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Malignancies
Interventions
DRUG:
YH002
Sponsor
Eucure (Beijing) Biopharma Co., Ltd